Such a test would better detect recurrence in a group of colon cancer patients whose metastases are hidden. The test, which uses the hormone receptor guanylyl cyclase C as a biomarker, is designed to determine who can benefit from adjuvant chemotherapy.
Adjuvant chemotherapy is used to eradicate whatever occult disease is left after surgery and other treatments.
“This approach can improve prognostic risk stratification and chemotherapeutic allocation for these colon cancer patients,” said Dr. Waldman, who is also chair of the department of pharmacology and experimental therapeutics at the university, and in the release. “With this CURE grant, we can now move a much-needed technology closer to commercialization, meaning closer to patients.”
The CURE grant is for almost $750,000.
Related Articles on Colon Cancer:
Study: Wealthier Patients Choose Colonoscopy Over Home-Based Fecal Occult Blood Test
Florida Hospital Flagler Now Offers Third Eye Colonoscopy
AGA Indentifies Five Treatments Physicians and Patients Should Question
